Trial Profile

A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Heparin; Warfarin
Indications Embolism; Stroke; Thrombosis
Focus Adverse reactions; Therapeutic Use
Acronyms EMANATE
Sponsors Pfizer

Most Recent Events

06 Apr 2018 Primary endpoint (Number of Participants With All Cause Death) has not been met as per the results published in the European Heart Journal.
06 Apr 2018 Primary endpoint (Number of Participants With Acute Stroke Event) has been met as per the results published in the European Heart Journal.
06 Apr 2018 Results published in the European Heart Journal

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com